Page last updated: 2024-11-13

gdc 0449

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24776445
CHEMBL ID473417
CHEBI ID66903
SCHEMBL ID302587
MeSH IDM0533197

Synonyms (97)

Synonym
HY-10440
2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
bdbm50249522
gdc-0449 ,
rg-3616
vismodegib ,
erivedge
hh-antag691
gdc-449
cur-691
r-3616
nsc-747691
chebi:66903 ,
nsc-755986
CHEMBL473417 ,
nsc747691
2-chloro-n-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide
NCGC00242497-01
nsc 747691
rg 3616
r 3616
gdc 0449
hhantag691
gdc0449
879085-55-9
erivedge (tn)
vismodegib (usan/inn)
D09992
benzamide, 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-
vismodegib [usan:inn]
hsdb 8130
unii-25x868m3ds
25x868m3ds ,
nsc755986
2-chloro-n-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide
vismodegib, free base
v-4050
AKOS015966534
BCP9000713
FT-0675833
BCPP000223
gdc-0449,vismodegib, hhantag691
NCGC00242497-02
PB15086
2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-
methanesulfonylbenzamide
vismodegib [usan]
vismodegib [inn]
vismodegib [vandf]
2-chloro-n-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
vismodegib [who-dd]
vismodegib [orange book]
vismodegib [mi]
2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide
vismodegibum
CS-0255
2-chloro-n-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
S1082
2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide
gtpl6975
2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
DB08828
SCHEMBL302587
smr004703564
MLS006012035
2-chloro-n-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide
BPQMGSKTAYIVFO-UHFFFAOYSA-N
vismodegib (gdc-0449)
hhantag 691
AC-26969
HMS3604K16
AB01565813_02
2-chloranyl-~{n}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide
vis ,
mfcd12407408
J-509076
DTXSID40236689 ,
2-chloro-n-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide
sr-01000941574
SR-01000941574-1
HMS3654E17
NCGC00242497-06
SW218087-2
EX-A2178
vismodegib; gdc-0449
2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide
AS-14066
BCP01715
Q2070286
CCG-264811
NCGC00242497-12
nsc755809
nsc-755809
l01xx43
dtxcid20159180
hedgehog antagonist gdc-0449
EN300-7413185

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance), weight loss, and fatigue."( Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Arron, ST; Chang, AL; Dirix, L; Friedlander, PA; Graham, RA; Hainsworth, JD; Hauschild, A; Lewis, KD; Low, JA; Mackey, HM; Marmur, E; Migden, MR; Oro, AE; Reddy, JC; Rudin, CM; Sekulic, A; Solomon, JA; Yauch, RL; Yoo, S, 2012
)
0.38
" Unfortunately, vismodegib has notable adverse effects (especially those of alopecia, gastrointestinal, muscle spasms, and dysguesia) that make dermatologists reluctant to prescribe the drug and patients unwilling to undergo therapy."( Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
Juhasz, ML; Marmur, ES, 2014
)
0.4
" However, severe and numerous adverse events are associated with vismodegib use."( Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
Ash, MM; Jolly, PS, 2015
)
0.42
"Herein, we describe a potential serious adverse effect associated with vismodegib use."( Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
Ash, MM; Jolly, PS, 2015
)
0.42
" Muscle spasms (76%), alopecia (58%), and dysgeusia (50%) were the most frequent adverse events (AEs)."( A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Caro, I; Egbert, B; Goldberg, LH; Gross, KG; Hamilton, TK; Hou, J; Lyons, B; Sharata, H; Sofen, H, 2015
)
0.42
" Adverse events (AEs) commonly observed in hedgehog pathway inhibitor (HPI)-treated patients include muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and asthenia (fatigue)."( Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Ascierto, PA; Basset-Seguin, N; Dréno, B; Dummer, R; Ernst, S; Fife, K; Hauschild, A; Kunstfeld, R; Lacouture, ME; Licitra, L; Neves, RI; Peris, K; Puig, S; Sekulic, A; Sokolof, J, 2016
)
0.43
" However, the nature of the low-grade adverse events (AEs) commonly observed in HPI-treated patients, including muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and fatigue, can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation."( Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Ascierto, PA; Basset-Seguin, N; Dréno, B; Dummer, R; Ernst, S; Fife, K; Hauschild, A; Kunstfeld, R; Lacouture, ME; Licitra, L; Neves, RI; Peris, K; Puig, S; Sekulic, A; Sokolof, J, 2016
)
0.43
" We examined the best overall response rate (BORR) and adverse events (AEs) of vismodegib in patients with advanced BCC (aBCC) with and without BCCNS."( Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Arron, ST; Chang, AL; Day, BM; McKenna, EF; Migden, MR; Sekulic, A; Solomon, JA; Yoo, S, 2016
)
0.43
" An UK expert panel met to discuss management strategies for adverse events associated with vismodegib (most commonly taste disturbances, muscle cramps and alopecia)."( Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Fife, K; Herd, R; Jones, S; Lalondrelle, S; Lear, JT; Plummer, R; Strong, A, 2017
)
0.46
" Safety was similar in both groups, although those aged ≥65 years had a higher percentage of grade 3-5 adverse events than those aged <65 years."( Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Arron, ST; Chang, AL; Day, BM; Lewis, KD; McKenna, EF; Migden, MR; Sekulic, A; Solomon, JA; Yoo, S, 2016
)
0.43
"Our objective was to identify evidence of hepatotoxicity with vismodegib in the FDA Adverse Event Reporting System (FAERS) in treated patients in two National Cancer Institute Comprehensive Cancer Centers."( Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.
Arabyat, R; Edwards, BJ; Hammel, JA; Raisch, DW; Saraykar, SS; Sun, M; Tran, HT; Wehr, N; West, DP, 2017
)
0.46
"Two cases of severe liver dysfunction were published (Common Terminology Criteria for Adverse Events [CTCAE] class III), and 94 reports of adverse events (AEs) were detected in FAERS, 35 of which were serious AEs."( Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.
Arabyat, R; Edwards, BJ; Hammel, JA; Raisch, DW; Saraykar, SS; Sun, M; Tran, HT; Wehr, N; West, DP, 2017
)
0.46
" Adverse events remained consistent with clinical experience."( Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Basset-Seguin, N; Dimier, N; Garbe, C; Gesierich, A; Hamid, O; Hauschild, A; Hou, J; Lao, CD; McKenna, E; Migden, MR; Miller, C; Mortier, L; Murrell, DF; Quevedo, JF; Schadendorf, D; Sekulic, A; Williams, S, 2017
)
0.46
" The study was influenced by the high number of patients with hepatocellular carcinoma with advanced cirrhosis; rendering it difficult to draw any causal relationships between vismodegib exposure and the serious adverse events."( Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa, GK; Chandra, P; Cheeti, S; Colburn, D; Graham, RA; Lewis, LD; LoRusso, P; Maitland, M; Simmons, B; Williams, S, 2017
)
0.46
" The most common adverse events were muscle spasm (100% of patients), alopecia (70%), dysgeusia (50%), thrombocytopenia (50%), and nausea (40%); these events were predominantly grade 1/2."( A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Benevolo, G; Couban, S; Cultrera, J; Dimier, N; Donnellan, W; Hertig, C; Hooper, G; Koschmieder, S; Malhi, V; Passamonti, F; Tandon, M; Verstovsek, S, 2018
)
0.48
" Vismodegib has been shown to be a safe and well tolerated treatment option for elderly patients affected by multiple comorbidities and advanced BCC."( Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Bianchi, L; Fargnoli, MC; Gutierrez, C; Peris, K; Piccerillo, A; Sollena, P; Spallone, G; Tambone, S; Ventura, A, 2019
)
0.51
" In this article, we systematically evaluated the performance of three different models in longitudinal muscle spasm adverse event (AE) data obtained from a clinical trial for vismodegib: a proportional odds (PO) model, a discrete-time Markov model, and a continuous-time Markov model."( Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.
Jin, JY; Kågedal, M; Lu, T; Yang, Y, 2020
)
0.56
"2%) patients had at least one adverse event (AE)."( Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
Carrizo, M; Cozzani, R; Del Aguila, R; Gonzalez, A; Sanchez, S, 2020
)
0.56
" A total of 340 adverse events were reported in 63 (95."( Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.
Berking, C; Gutzmer, R; Häckl, M; Haferkamp, S; Hauschild, A; Herbst, R; Leiter, U; Meier, F; Schadendorf, D; Schulze, HJ; Ulrich, C; Wahl, RU, 2021
)
0.62
" Most adverse events were mild to moderate."( Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Gutzmer, R; Herbst, R; Kaatz, M; Kreuter, A; Leiter, U; Livingstone, E; Mohr, P; Pföhler, C; Schadendorf, D; Ulrich, J; Utikal, JS; Weichenthal, M, 2022
)
0.72
" The secondary aims of the study were the disease control rate, the incidence of adverse events (AEs) and the estimation of the factors that potentially impact the treatment outcome and patient survival."( Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study.
Cybulska-Stopa, B; Czarnecka, I; Dudzisz-Śledź, M; Koseła-Paterczyk, H; Kowalczyk, A; Mackiewicz, J; Owczarek, W; Paluchowska, E; Pietruszka, A; Rogala, P; Rutkowski, P; Składowski, K; Sobczuk, P; Świtaj, T; Słowińska, M; Łasińska, I, 2022
)
0.72
" For safety assessment, the prevalence of the following adverse effects was analyzed: muscle spasms, dysgeusia, alopecia, weight loss, fatigue, nausea, myalgias, vomiting, skin squamous cell carcinoma, increased creatine kinase, diarrhea, decreased appetite, and amenorrhea."( Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).
Lefrançois, P; Litvinov, IV; Nguyen, A; Xie, P, 2023
)
0.91
" The most common adverse effects for vismodegib and sonidegib were muscle spasms (70."( Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).
Lefrançois, P; Litvinov, IV; Nguyen, A; Xie, P, 2023
)
0.91
" Monthly follow-up was performed, and we registered the clinical evolution and adverse reactions."( Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.
Almazán-Fernández, FM; Ayén-Rodríguez, A; Linares-González, L; Llamas-Segura, C; Ruiz-Villaverde, R, 2023
)
0.91
" Most patients (83%) had at least one adverse event, and two needed dose adjustment temporarily or permanently to continue."( Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.
Almazán-Fernández, FM; Ayén-Rodríguez, A; Linares-González, L; Llamas-Segura, C; Ruiz-Villaverde, R, 2023
)
0.91
"Vismodegib is a safe and effective treatment for locally advanced BCC, and its role in unresectable BCC seems to be an important option in these challenging cases."( Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.
Almazán-Fernández, FM; Ayén-Rodríguez, A; Linares-González, L; Llamas-Segura, C; Ruiz-Villaverde, R, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"Factors determining the pharmacokinetics of 2-chloro-N-(4-chloro-3-(pyridine-2-yl)phenyl)-4-(methylsulfonyl)benzamide (GDC-0449) were investigated using preclinical studies and physiologically based pharmacokinetic (PBPK) modeling."( Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.
Cui, Y; Deng, Y; Hop, CE; Khojasteh, SC; La, H; Marsters, JC; Morinello, EJ; Song, X; Theil, FP; Vernillet, L; Wang, H; Wong, H, 2010
)
0.36
"Sixty-eight patients received GDC-0449 at 150 (n = 41), 270 (n = 23), or 540 (n = 4) mg/d, with pharmacokinetic (PK) sampling at multiple time points."( Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Cheeti, S; Graham, RA; Jin, JY; Jorga, K; Lorusso, PM; Low, JA; Lum, BL; Reddy, JC; Rudin, CM; Von Hoff, DD, 2011
)
0.37
"Understanding of plasma protein binding will provide mechanistic insights into drug interactions or unusual pharmacokinetic properties."( Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.
Li, J; Lorusso, PM; Matherly, LH; Wu, J, 2012
)
0.38
" The effect of vismodegib on rosiglitazone and OC pharmacokinetic parameters (primary objective) was evaluated through pharmacokinetic sampling over a 24-h period (Days 1 and 8)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
" We conducted a pharmacokinetic study of vismodegib in patients with advanced solid tumors to explore the effects of food on drug exposure."( Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Cohen, EE; Geary, D; Graham, RA; Kang, SP; Karrison, TG; Kell, B; Maitland, ML; Ratain, MJ; Schilsky, RL; Sharma, MR; Takebe, N; Turcich, M; Wu, K, 2013
)
0.39
"A HF meal increases plasma exposure to a single dose of vismodegib, but there are no pharmacokinetic or safety differences between fasting and fed groups at steady-state."( Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Cohen, EE; Geary, D; Graham, RA; Kang, SP; Karrison, TG; Kell, B; Maitland, ML; Ratain, MJ; Schilsky, RL; Sharma, MR; Takebe, N; Turcich, M; Wu, K, 2013
)
0.39
"Obtaining pharmacokinetic data from the intravenous route for drugs intended for oral administration has traditionally been expensive and time consuming because of the toxicology requirements and challenges in intravenous formulations."( Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.
Lappin, G, 2016
)
0.43
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016
)
0.43
" The primary outcome was the pharmacodynamic assessment of Gli1 mRNA suppression with vismodegib in tumor tissue."( Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
Antonarakis, ES; Boudadi, K; Demarzo, A; Eisenberger, M; Glavaris, S; Harb, R; Hughes, R; Luber, B; Maughan, BL; Paller, C; Ross, A; Sullivan, R; Suzman, DL; Wang, H, 2016
)
0.43
" Despite this pharmacodynamic response that indicated target inhibition in some patients, there was no apparent signal of clinical activity."( Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.
Antonarakis, ES; Boudadi, K; Demarzo, A; Eisenberger, M; Glavaris, S; Harb, R; Hughes, R; Luber, B; Maughan, BL; Paller, C; Ross, A; Sullivan, R; Suzman, DL; Wang, H, 2016
)
0.43
"To determine the pharmacokinetic parameters and biodistribution of GDC-0449 loaded polymeric micelles after systemic administration into common bile duct ligation (CBDL) induced liver fibrotic mice."( Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.
Dutta, R; Evande, RE; Grem, JL; Kumar, V; Mahato, RI; Peng, Y, 2017
)
0.46
" In this work, analogs of Vismodegib with deuterium-for-hydrogen replacement at certain metabolically active sites were prepared and found to have a better pharmacokinetic properties in mice."( Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
Chen, Y; Deng, Y; Jiang, H; Wang, F; Yu, J; Zhan, M; Zhao, L, 2018
)
0.48
"Vismodegib displays unique pharmacokinetic characteristics including saturable plasma protein binding to alpha-1 acid glycoprotein (AAG) and apparent time-dependent bioavailability leading to non-linear PK with dose and time, significantly faster time to steady-state and lower than predicted accumulation."( A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-Dependent Solubility and Nonsink Permeation.
Chen, Y; Chiang, PC; Dolton, MJ; Jin, JY; Ma, F, 2020
)
0.56
" Oral physiologically based pharmacokinetic (PBPK) models were built using preclinical in vitro and in vivo data and successfully predicted the oral PK profiles in rats, dogs, and monkeys."( Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
Hop, CECA; Lin, L; Wong, H; Wright, MR, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)."( Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
Colburn, D; Colevas, AD; Graham, RA; LoRusso, PM; Low, JA; Malhi, V; Mita, M; Piha-Paul, SA; Yin, M, 2013
)
0.39
"The results of this study suggest that vismodegib can be administered with acid-reducing agents and P-gp and CYP inhibitors without the risk of a clinically meaningful pharmacokinetic drug-drug interaction."( A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Chandra, P; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Malhi, V; Williams, SJ, 2016
)
0.43
"Patients with newly diagnosed extensive-stage small cell lung cancer (SCLC-ED) were randomized to receive four 21-day cycles of cisplatin and etoposide alone (cisplatin at 75 mg/m(2) on day 1 and etoposide at 100 mg/m(2) on days 1-3; arm A) or in combination with either vismodegib (150 mg/d by mouth; arm B) or cixutumumab (6 mg/kg/wk intravenously on day 1; arm C)."( Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Belani, CP; Chen, HX; Dahlberg, SE; Fleisher, M; Hann, CL; Monga, M; Ramalingam, SS; Rudin, CM; Schiller, JH; Shanks, JC; Sturtz, K; Takebe, N; Tester, WJ; Velasco, MR, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability ranged from 13% in monkeys to 53% in dogs."( Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Chen, JZ; Chou, B; Halladay, JS; Kenny, JR; Khojasteh, SC; La, H; Marsters, JC; Plise, E; Robarge, K; Rudewicz, PJ; Shin, Y; Wong, H; Wong, S; Zhang, C, 2009
)
0.35
" dose, mean clearance, volume of distribution and absolute bioavailability were 43."( Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Borin, MT; Chang, I; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Low, JA; Lum, BL; Malhi, V; Shin, YG, 2012
)
0.38
" administration, moderate absolute bioavailability and non-linear PK after repeated dosing."( Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Borin, MT; Chang, I; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Low, JA; Lum, BL; Malhi, V; Shin, YG, 2012
)
0.38
"Vismodegib, an orally bioavailable small-molecule Smoothened inhibitor, is approved for treatment of advanced basal cell carcinoma (BCC)."( Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Cohen, EE; Geary, D; Graham, RA; Kang, SP; Karrison, TG; Kell, B; Maitland, ML; Ratain, MJ; Schilsky, RL; Sharma, MR; Takebe, N; Turcich, M; Wu, K, 2013
)
0.39
" Agents that increase gastrointestinal pH may reduce the solubility and bioavailability of vismodegib."( Vismodegib for the treatment of basal cell skin cancer.
Kolesar, JM; Poggi, L, 2013
)
0.39
" Vismodegib (GDC-0449) is an orally bioavailable hedgehog pathway inhibitor that selectively inhibits SMO."( Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti, C; Plaka, M; Stratigos, AJ, 2014
)
0.4
" Such studies are necessary, however, particularly when regulator agencies request absolute bioavailability data."( Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.
Lappin, G, 2016
)
0.43
" Furthermore, compound 24 showed excellent PK profiles with a 72% oral bioavailability in beagle dogs."( Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Li, J; Liu, Y; Lu, W; Luo, L; Ma, H; Sun, Z; Tian, S; Yang, ZJ; Zhang, H; Zhang, X; Zheng, J, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Vismodegib displays unique pharmacokinetic characteristics including saturable plasma protein binding to alpha-1 acid glycoprotein (AAG) and apparent time-dependent bioavailability leading to non-linear PK with dose and time, significantly faster time to steady-state and lower than predicted accumulation."( A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-Dependent Solubility and Nonsink Permeation.
Chen, Y; Chiang, PC; Dolton, MJ; Jin, JY; Ma, F, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"Oral dosing of vismodegib caused tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent CRC models, D5123, and 1040830."( Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Alicke, B; de Sauvage, FJ; Gould, SE; Januario, T; La, H; Pacheco, P; West, KA; Wong, H; Yauch, RL, 2011
)
0.37
"This study was designed to evaluate whether less frequent dosing [three times per week (TIW) or once weekly (QW)] of 150 mg vismodegib following a loading dose [150 mg once daily (QD) for 11 days] would result in similar safety, tolerability, and steady-state levels of total and unbound vismodegib as continuous QD dosing."( Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Adjei, A; Berlin, J; Chang, I; Cheeti, S; Colburn, D; Dy, G; Graham, RA; Jimeno, A; Jin, JY; Leichman, L; Lorusso, PM; Low, JA, 2011
)
0.37
"The most frequently reported adverse events were consistent with those in prior monotherapy trials, with similar incidence and severity regardless of dosing schedule."( Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Adjei, A; Berlin, J; Chang, I; Cheeti, S; Colburn, D; Dy, G; Graham, RA; Jimeno, A; Jin, JY; Leichman, L; Lorusso, PM; Low, JA, 2011
)
0.37
" Finally, we demonstrated that GDC-0449 decreased HCV RNA levels in a dose-response manner."( Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication.
Bradrick, S; Chaturvedi, G; Choi, SS; Diehl, AM; Jhaveri, R; Mostafavi, A; Qiang, G; Weinman, SA, 2011
)
0.37
" The objective of this study was to determine whether vismodegib PK change following repeated dosing by administering a tracer intravenous (i."( Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Borin, MT; Chang, I; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Low, JA; Lum, BL; Malhi, V; Shin, YG, 2012
)
0.38
" PK parameters after single and multiple oral dosing showed similar half-life, increased clearance and volume of distribution (81% and 63% higher, respectively) and decreased bioavailability (77% lower) after repeated dosing."( Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Borin, MT; Chang, I; Colburn, D; Dresser, MJ; Graham, RA; Hop, CE; Low, JA; Lum, BL; Malhi, V; Shin, YG, 2012
)
0.38
"There was no effect of vismodegib on the QTc interval when dosed daily at 150 mg to steady state."( Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
Ayache, JA; Chang, I; Dresser, MJ; Dufek, MB; Ezzet, F; Graham, RA; Jin, JY; Low, JA; Wang, B; Zerivitz, K, 2013
)
0.39
" Nevertheless, further investigation on new molecules and the effectiveness of an intermittent dosing regimen is necessary."( Basal cell carcinoma: a paradigm for targeted therapies.
Barysch, M; Dreier, J; Dummer, R; Felderer, L; Rozati, S, 2013
)
0.39
" Vismodegib is available as a 150-mg capsule, and the approved dosage is 150 mg orally once daily."( Vismodegib for the treatment of basal cell skin cancer.
Kolesar, JM; Poggi, L, 2013
)
0.39
" However, vismodegib's novel mechanism of action, oral dosage form, preliminary efficacy, and tolerability compared with cytotoxic chemotherapy may make it an attractive candidate for the treatment of other cancers."( Vismodegib for the treatment of basal cell skin cancer.
Kolesar, JM; Poggi, L, 2013
)
0.39
" Twenty eligible patients were enrolled in the flat-dosing part of the study: 10 at each dosage level."( Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Boyett, JM; Chintagumpala, M; Curran, T; Ellison, DW; Gajjar, A; Gilbertson, RJ; Goldman, S; Kaste, S; Kun, LE; Packer, RJ; Stewart, CF; Takebe, N; Wallace, D, 2013
)
0.39
" Ongoing clinical trials aim to explore the role of vismodegib in the neoadjuvant setting prior to surgery, the potential use of alternate dosing regimens in order to limit chronic adverse events, as well as the identification of patients with BCC that are more likely to respond to this targeted therapy based on genotypic and/or phenotypic characteristics."( Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti, C; Plaka, M; Stratigos, AJ, 2014
)
0.4
" Safety was comparable when dosed continuously versus intermittently."( A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Caro, I; Egbert, B; Goldberg, LH; Gross, KG; Hamilton, TK; Hou, J; Lyons, B; Sharata, H; Sofen, H, 2015
)
0.42
" A method has emerged whereby the drug administered intravenously is isotopically labeled and dosed at a maximum of 100 µg concomitantly with an oral administration given at a therapeutically relevant level."( Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.
Lappin, G, 2016
)
0.43
" In vitro experiments suggested that concurrent dosing showed stronger synergy than sequential dosing."( The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Al-Kali, A; Bhagavatula, K; Bogenberger, JM; Delman, DH; Foran, JM; Hansen, N; Mesa, RA; Mohan, J; Oliver, GR; Rakhshan, F; Tibes, R; Wood, T, 2015
)
0.42
" Additional endpoints for this phase were: whether continuous versus interrupted dosing differentially affected tumour burden; time to reach various levels of reduction in tumour burden; reduction in tumour size in patients who took less than 50% of the expected number of vismodegib tablets; reduction in the number of surgical excisions required per year before, during, and after treatment; and the effect of vismodegib on hedgehog target gene expression."( Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Ally, MS; Aszterbaum, M; Bickers, DR; Chanana, AM; Clark, C; Epstein, EH; Gildengorin, G; Lindgren, JA; Mackay-Wiggan, JM; Marji, J; Rezaee, MR; Tang, JY; Ulerio, G, 2016
)
0.43
" Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vismodegib continuously than in those who interrupted dosing (mean 0·6 [0·72] new surgically eligible basal-cell carcinomas per patient per year vs 1·7 [1·8] new surgically eligible basal-cell carcinomas per patient per year, p<0·0001)."( Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Ally, MS; Aszterbaum, M; Bickers, DR; Chanana, AM; Clark, C; Epstein, EH; Gildengorin, G; Lindgren, JA; Mackay-Wiggan, JM; Marji, J; Rezaee, MR; Tang, JY; Ulerio, G, 2016
)
0.43
" We assessed the safety and activity of two long-term intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas."( Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Bergström, D; Dréno, B; Fosko, S; Gilberg, F; Grob, JJ; Hauschild, A; Kunstfeld, R; Labeille, B; Page, DR; Puig, S; Rogers, G; Schadendorf, D; Zloty, D, 2017
)
0.46
"Both intermittent dosing schedules of vismodegib seemed to show good activity in long-term regimens in patients with multiple basal-cell carcinomas."( Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Bergström, D; Dréno, B; Fosko, S; Gilberg, F; Grob, JJ; Hauschild, A; Kunstfeld, R; Labeille, B; Page, DR; Puig, S; Rogers, G; Schadendorf, D; Zloty, D, 2017
)
0.46
" Compound 24 has a lower melting point and much greater solubility compared with vismodegib, resulting in linear PK profiles when dosed orally at 10, 30, and 100 mg/kg in rats."( Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Li, J; Liu, Y; Lu, W; Luo, L; Ma, H; Sun, Z; Tian, S; Yang, ZJ; Zhang, H; Zhang, X; Zheng, J, 2017
)
0.46
" However, the inhibition dosage of SMO and PI3K/Akt depended on the activity of phosphodiesterases (PDEs)."( A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh, A; Friedman, R; Jensen, R, 2018
)
0.48
" A notable difference between sonidegib and vismodegib is their respective pharmacokinetic profiles with sonidegib reaching peak concentration in plasma within 2–4 hours of dosing and steady state in plasma achieved by week 17 of treatment, while vismodegib reaches peak plasma concentration approximately 2 days after a single dose and steady state within 21 days of repeated dosing."( A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Dummer, R; Farberg, AS; Hanke, CW; Migden, M; Squittieri, N, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
SMO receptor antagonistAn antagonist that interferes with the action of smoothened (SMO) receptor.
Hedgehog signaling pathway inhibitorAny pathway inhibitor that inhibits the Hedgehog signalling pathway.
teratogenic agentA role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
benzamides
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency1.42160.001310.157742.8575AID1259252; AID1259253; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)20.00000.00011.774010.0000AID1650656
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)20.00000.00011.753610.0000AID1650652
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)20.00000.00002.015110.0000AID1650653
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)20.00000.00002.800510.0000AID1650654
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.02000.00070.97749.7000AID1075722
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.02000.00030.81978.4900AID1075722
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)20.00000.00002.398310.0000AID1650655
Smoothened homologMus musculus (house mouse)IC50 (µMol)0.07000.00120.37681.9000AID1239805; AID1325018; AID1360315; AID1383186; AID1595364; AID1771775; AID668854; AID695428
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)33.00000.00091.901410.0000AID1650624
Sonic hedgehog proteinHomo sapiens (human)IC50 (µMol)0.88250.01500.59301.7500AID596607; AID596608
Sonic hedgehog proteinMus musculus (house mouse)IC50 (µMol)0.00770.00301.19115.0000AID1057692; AID351760; AID447684
Smoothened homologHomo sapiens (human)IC50 (µMol)0.02220.00040.16401.5000AID1075722; AID1075724; AID1140464; AID1595365; AID1650665; AID1667114; AID661553; AID661558
Smoothened homologHomo sapiens (human)Ki0.01420.00600.06570.2320AID1458765; AID695425
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)1.40000.00401.966610.0000AID1873212
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd65.37500.08933.31358.0000AID596685; AID596691; AID596696; AID596704
AlbuminRattus norvegicus (Norway rat)Kd105.60001.47006.53179.3100AID596687; AID596698; AID596699
Smoothened homologMus musculus (house mouse)EC50 (µMol)0.00340.00200.16390.8000AID1650619; AID1650663
Smoothened homologHomo sapiens (human)EC50 (µMol)0.00250.00200.00250.0030AID1650631; AID1650662
Smoothened homologHomo sapiens (human)Kd0.09750.01240.07530.1160AID1665032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)INH20.00001.70002.85004.0000AID526558
Cytochrome P450 2C9 Homo sapiens (human)INH20.00004.40007.00009.1000AID526559
Sonic hedgehog proteinHomo sapiens (human)INH0.00280.00280.00280.0028AID447691
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (276)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISonic hedgehog proteinHomo sapiens (human)
epithelial-mesenchymal cell signalingSonic hedgehog proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IISonic hedgehog proteinHomo sapiens (human)
branching involved in blood vessel morphogenesisSonic hedgehog proteinHomo sapiens (human)
vasculogenesisSonic hedgehog proteinHomo sapiens (human)
metanephros developmentSonic hedgehog proteinHomo sapiens (human)
branching involved in ureteric bud morphogenesisSonic hedgehog proteinHomo sapiens (human)
cell fate specificationSonic hedgehog proteinHomo sapiens (human)
neural crest cell migrationSonic hedgehog proteinHomo sapiens (human)
heart loopingSonic hedgehog proteinHomo sapiens (human)
positive regulation of neuroblast proliferationSonic hedgehog proteinHomo sapiens (human)
osteoblast developmentSonic hedgehog proteinHomo sapiens (human)
lymphoid progenitor cell differentiationSonic hedgehog proteinHomo sapiens (human)
determination of left/right asymmetry in lateral mesodermSonic hedgehog proteinHomo sapiens (human)
protein import into nucleusSonic hedgehog proteinHomo sapiens (human)
endocytosisSonic hedgehog proteinHomo sapiens (human)
smoothened signaling pathwaySonic hedgehog proteinHomo sapiens (human)
cell-cell signalingSonic hedgehog proteinHomo sapiens (human)
pattern specification processSonic hedgehog proteinHomo sapiens (human)
ectoderm developmentSonic hedgehog proteinHomo sapiens (human)
neuroblast proliferationSonic hedgehog proteinHomo sapiens (human)
axon guidanceSonic hedgehog proteinHomo sapiens (human)
central nervous system developmentSonic hedgehog proteinHomo sapiens (human)
ventral midline developmentSonic hedgehog proteinHomo sapiens (human)
hindgut morphogenesisSonic hedgehog proteinHomo sapiens (human)
heart developmentSonic hedgehog proteinHomo sapiens (human)
blood coagulationSonic hedgehog proteinHomo sapiens (human)
androgen metabolic processSonic hedgehog proteinHomo sapiens (human)
positive regulation of cell population proliferationSonic hedgehog proteinHomo sapiens (human)
embryonic pattern specificationSonic hedgehog proteinHomo sapiens (human)
polarity specification of anterior/posterior axisSonic hedgehog proteinHomo sapiens (human)
dorsal/ventral pattern formationSonic hedgehog proteinHomo sapiens (human)
positive regulation of gene expressionSonic hedgehog proteinHomo sapiens (human)
negative regulation of gene expressionSonic hedgehog proteinHomo sapiens (human)
oligodendrocyte developmentSonic hedgehog proteinHomo sapiens (human)
striated muscle tissue developmentSonic hedgehog proteinHomo sapiens (human)
skeletal muscle cell proliferationSonic hedgehog proteinHomo sapiens (human)
positive regulation of skeletal muscle cell proliferationSonic hedgehog proteinHomo sapiens (human)
intein-mediated protein splicingSonic hedgehog proteinHomo sapiens (human)
protein autoprocessingSonic hedgehog proteinHomo sapiens (human)
spinal cord dorsal/ventral patterningSonic hedgehog proteinHomo sapiens (human)
spinal cord motor neuron differentiationSonic hedgehog proteinHomo sapiens (human)
thalamus developmentSonic hedgehog proteinHomo sapiens (human)
dorsal/ventral neural tube patterningSonic hedgehog proteinHomo sapiens (human)
cerebellar granule cell precursor proliferationSonic hedgehog proteinHomo sapiens (human)
positive regulation of cerebellar granule cell precursor proliferationSonic hedgehog proteinHomo sapiens (human)
telencephalon regionalizationSonic hedgehog proteinHomo sapiens (human)
regulation of proteolysisSonic hedgehog proteinHomo sapiens (human)
positive regulation of Wnt signaling pathwaySonic hedgehog proteinHomo sapiens (human)
lung developmentSonic hedgehog proteinHomo sapiens (human)
embryonic limb morphogenesisSonic hedgehog proteinHomo sapiens (human)
negative regulation of cell migrationSonic hedgehog proteinHomo sapiens (human)
male genitalia developmentSonic hedgehog proteinHomo sapiens (human)
prostate gland developmentSonic hedgehog proteinHomo sapiens (human)
thyroid gland developmentSonic hedgehog proteinHomo sapiens (human)
forebrain developmentSonic hedgehog proteinHomo sapiens (human)
midbrain developmentSonic hedgehog proteinHomo sapiens (human)
hindbrain developmentSonic hedgehog proteinHomo sapiens (human)
pancreas developmentSonic hedgehog proteinHomo sapiens (human)
hair follicle morphogenesisSonic hedgehog proteinHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processSonic hedgehog proteinHomo sapiens (human)
T cell differentiation in thymusSonic hedgehog proteinHomo sapiens (human)
negative regulation of T cell differentiation in thymusSonic hedgehog proteinHomo sapiens (human)
positive regulation of T cell differentiation in thymusSonic hedgehog proteinHomo sapiens (human)
positive regulation of immature T cell proliferation in thymusSonic hedgehog proteinHomo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IISonic hedgehog proteinHomo sapiens (human)
embryonic forelimb morphogenesisSonic hedgehog proteinHomo sapiens (human)
embryonic hindlimb morphogenesisSonic hedgehog proteinHomo sapiens (human)
trunk neural crest cell migrationSonic hedgehog proteinHomo sapiens (human)
T cell proliferationSonic hedgehog proteinHomo sapiens (human)
regulation of cell population proliferationSonic hedgehog proteinHomo sapiens (human)
negative regulation of T cell proliferationSonic hedgehog proteinHomo sapiens (human)
positive regulation of protein import into nucleusSonic hedgehog proteinHomo sapiens (human)
odontogenesis of dentin-containing toothSonic hedgehog proteinHomo sapiens (human)
regulation of odontogenesisSonic hedgehog proteinHomo sapiens (human)
embryonic digit morphogenesisSonic hedgehog proteinHomo sapiens (human)
camera-type eye developmentSonic hedgehog proteinHomo sapiens (human)
negative regulation of apoptotic processSonic hedgehog proteinHomo sapiens (human)
CD4-positive or CD8-positive, alpha-beta T cell lineage commitmentSonic hedgehog proteinHomo sapiens (human)
positive thymic T cell selectionSonic hedgehog proteinHomo sapiens (human)
negative thymic T cell selectionSonic hedgehog proteinHomo sapiens (human)
intermediate filament organizationSonic hedgehog proteinHomo sapiens (human)
myoblast differentiationSonic hedgehog proteinHomo sapiens (human)
negative regulation of cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of smoothened signaling pathwaySonic hedgehog proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionSonic hedgehog proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IISonic hedgehog proteinHomo sapiens (human)
alpha-beta T cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationSonic hedgehog proteinHomo sapiens (human)
negative regulation of alpha-beta T cell differentiationSonic hedgehog proteinHomo sapiens (human)
cell developmentSonic hedgehog proteinHomo sapiens (human)
thymus developmentSonic hedgehog proteinHomo sapiens (human)
embryonic digestive tract morphogenesisSonic hedgehog proteinHomo sapiens (human)
embryonic foregut morphogenesisSonic hedgehog proteinHomo sapiens (human)
positive regulation of skeletal muscle tissue developmentSonic hedgehog proteinHomo sapiens (human)
animal organ formationSonic hedgehog proteinHomo sapiens (human)
neuron fate commitmentSonic hedgehog proteinHomo sapiens (human)
embryonic skeletal system developmentSonic hedgehog proteinHomo sapiens (human)
positive regulation of astrocyte differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of oligodendrocyte differentiationSonic hedgehog proteinHomo sapiens (human)
smooth muscle tissue developmentSonic hedgehog proteinHomo sapiens (human)
branching morphogenesis of an epithelial tubeSonic hedgehog proteinHomo sapiens (human)
inner ear developmentSonic hedgehog proteinHomo sapiens (human)
formation of anatomical boundarySonic hedgehog proteinHomo sapiens (human)
stem cell developmentSonic hedgehog proteinHomo sapiens (human)
positive regulation of striated muscle cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of cell divisionSonic hedgehog proteinHomo sapiens (human)
Bergmann glial cell differentiationSonic hedgehog proteinHomo sapiens (human)
roof of mouth developmentSonic hedgehog proteinHomo sapiens (human)
canonical Wnt signaling pathwaySonic hedgehog proteinHomo sapiens (human)
limb bud formationSonic hedgehog proteinHomo sapiens (human)
regulation of glial cell proliferationSonic hedgehog proteinHomo sapiens (human)
lung epithelium developmentSonic hedgehog proteinHomo sapiens (human)
trachea morphogenesisSonic hedgehog proteinHomo sapiens (human)
branching involved in salivary gland morphogenesisSonic hedgehog proteinHomo sapiens (human)
bud outgrowth involved in lung branchingSonic hedgehog proteinHomo sapiens (human)
right lung developmentSonic hedgehog proteinHomo sapiens (human)
left lung developmentSonic hedgehog proteinHomo sapiens (human)
lung lobe morphogenesisSonic hedgehog proteinHomo sapiens (human)
lung-associated mesenchyme developmentSonic hedgehog proteinHomo sapiens (human)
primary prostatic bud elongationSonic hedgehog proteinHomo sapiens (human)
prostate epithelial cord elongationSonic hedgehog proteinHomo sapiens (human)
salivary gland cavitationSonic hedgehog proteinHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisSonic hedgehog proteinHomo sapiens (human)
regulation of prostatic bud formationSonic hedgehog proteinHomo sapiens (human)
epithelial cell proliferation involved in prostate gland developmentSonic hedgehog proteinHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentSonic hedgehog proteinHomo sapiens (human)
regulation of mesenchymal cell proliferation involved in prostate gland developmentSonic hedgehog proteinHomo sapiens (human)
mesenchymal smoothened signaling pathway involved in prostate gland developmentSonic hedgehog proteinHomo sapiens (human)
artery developmentSonic hedgehog proteinHomo sapiens (human)
mesenchymal cell proliferation involved in lung developmentSonic hedgehog proteinHomo sapiens (human)
somite developmentSonic hedgehog proteinHomo sapiens (human)
positive regulation of sclerotome developmentSonic hedgehog proteinHomo sapiens (human)
cellular response to lithium ionSonic hedgehog proteinHomo sapiens (human)
dopaminergic neuron differentiationSonic hedgehog proteinHomo sapiens (human)
stem cell proliferationSonic hedgehog proteinHomo sapiens (human)
regulation of stem cell proliferationSonic hedgehog proteinHomo sapiens (human)
metanephric mesenchymal cell proliferation involved in metanephros developmentSonic hedgehog proteinHomo sapiens (human)
metanephric collecting duct developmentSonic hedgehog proteinHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySonic hedgehog proteinHomo sapiens (human)
establishment of epithelial cell polaritySonic hedgehog proteinHomo sapiens (human)
negative regulation of cholesterol effluxSonic hedgehog proteinHomo sapiens (human)
mesenchymal cell apoptotic processSonic hedgehog proteinHomo sapiens (human)
apoptotic signaling pathwaySonic hedgehog proteinHomo sapiens (human)
self proteolysisSonic hedgehog proteinHomo sapiens (human)
skeletal muscle fiber differentiationSonic hedgehog proteinHomo sapiens (human)
regulation of protein localization to nucleusSonic hedgehog proteinHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationSonic hedgehog proteinHomo sapiens (human)
tracheoesophageal septum formationSonic hedgehog proteinHomo sapiens (human)
negative regulation of ureter smooth muscle cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of ureter smooth muscle cell differentiationSonic hedgehog proteinHomo sapiens (human)
negative regulation of kidney smooth muscle cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of kidney smooth muscle cell differentiationSonic hedgehog proteinHomo sapiens (human)
positive regulation of mesenchymal cell proliferation involved in ureter developmentSonic hedgehog proteinHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processSonic hedgehog proteinHomo sapiens (human)
oligodendrocyte differentiationSonic hedgehog proteinHomo sapiens (human)
regulation of gene expressionSonic hedgehog proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IISmoothened homologHomo sapiens (human)
negative regulation of transcription by RNA polymerase IISmoothened homologHomo sapiens (human)
vasculogenesisSmoothened homologHomo sapiens (human)
osteoblast differentiationSmoothened homologHomo sapiens (human)
in utero embryonic developmentSmoothened homologHomo sapiens (human)
cell fate specificationSmoothened homologHomo sapiens (human)
neural crest cell migrationSmoothened homologHomo sapiens (human)
negative regulation of protein phosphorylationSmoothened homologHomo sapiens (human)
heart loopingSmoothened homologHomo sapiens (human)
positive regulation of neuroblast proliferationSmoothened homologHomo sapiens (human)
positive regulation of mesenchymal cell proliferationSmoothened homologHomo sapiens (human)
determination of left/right asymmetry in lateral mesodermSmoothened homologHomo sapiens (human)
type B pancreatic cell developmentSmoothened homologHomo sapiens (human)
protein import into nucleusSmoothened homologHomo sapiens (human)
apoptotic processSmoothened homologHomo sapiens (human)
G protein-coupled receptor signaling pathwaySmoothened homologHomo sapiens (human)
smoothened signaling pathwaySmoothened homologHomo sapiens (human)
ventral midline determinationSmoothened homologHomo sapiens (human)
neuroblast proliferationSmoothened homologHomo sapiens (human)
midgut developmentSmoothened homologHomo sapiens (human)
anterior/posterior pattern specificationSmoothened homologHomo sapiens (human)
gene expressionSmoothened homologHomo sapiens (human)
positive regulation of gene expressionSmoothened homologHomo sapiens (human)
negative regulation of gene expressionSmoothened homologHomo sapiens (human)
spinal cord dorsal/ventral patterningSmoothened homologHomo sapiens (human)
dentate gyrus developmentSmoothened homologHomo sapiens (human)
cerebellar cortex morphogenesisSmoothened homologHomo sapiens (human)
thalamus developmentSmoothened homologHomo sapiens (human)
dorsal/ventral neural tube patterningSmoothened homologHomo sapiens (human)
central nervous system neuron differentiationSmoothened homologHomo sapiens (human)
cerebral cortex developmentSmoothened homologHomo sapiens (human)
positive regulation of cell migrationSmoothened homologHomo sapiens (human)
negative regulation of epithelial cell differentiationSmoothened homologHomo sapiens (human)
hair follicle morphogenesisSmoothened homologHomo sapiens (human)
multicellular organism growthSmoothened homologHomo sapiens (human)
positive regulation of multicellular organism growthSmoothened homologHomo sapiens (human)
positive regulation of protein import into nucleusSmoothened homologHomo sapiens (human)
odontogenesis of dentin-containing toothSmoothened homologHomo sapiens (human)
negative regulation of apoptotic processSmoothened homologHomo sapiens (human)
negative regulation of DNA bindingSmoothened homologHomo sapiens (human)
positive regulation of smoothened signaling pathwaySmoothened homologHomo sapiens (human)
positive regulation of organ growthSmoothened homologHomo sapiens (human)
astrocyte activationSmoothened homologHomo sapiens (human)
skeletal muscle fiber developmentSmoothened homologHomo sapiens (human)
smooth muscle tissue developmentSmoothened homologHomo sapiens (human)
forebrain morphogenesisSmoothened homologHomo sapiens (human)
homeostasis of number of cells within a tissueSmoothened homologHomo sapiens (human)
epithelial cell proliferationSmoothened homologHomo sapiens (human)
positive regulation of epithelial cell proliferationSmoothened homologHomo sapiens (human)
protein stabilizationSmoothened homologHomo sapiens (human)
myoblast migrationSmoothened homologHomo sapiens (human)
negative regulation of hair follicle developmentSmoothened homologHomo sapiens (human)
contact inhibitionSmoothened homologHomo sapiens (human)
atrial septum morphogenesisSmoothened homologHomo sapiens (human)
mammary gland epithelial cell differentiationSmoothened homologHomo sapiens (human)
epithelial-mesenchymal cell signalingSmoothened homologHomo sapiens (human)
somite developmentSmoothened homologHomo sapiens (human)
pancreas morphogenesisSmoothened homologHomo sapiens (human)
left/right axis specificationSmoothened homologHomo sapiens (human)
cellular response to cholesterolSmoothened homologHomo sapiens (human)
dopaminergic neuron differentiationSmoothened homologHomo sapiens (human)
mesenchymal to epithelial transition involved in metanephric renal vesicle formationSmoothened homologHomo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesisSmoothened homologHomo sapiens (human)
regulation of somatic stem cell population maintenanceSmoothened homologHomo sapiens (human)
regulation of heart morphogenesisSmoothened homologHomo sapiens (human)
pattern specification processSmoothened homologHomo sapiens (human)
central nervous system developmentSmoothened homologHomo sapiens (human)
commissural neuron axon guidanceSmoothened homologHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (79)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endopeptidase activitySonic hedgehog proteinHomo sapiens (human)
patched bindingSonic hedgehog proteinHomo sapiens (human)
calcium ion bindingSonic hedgehog proteinHomo sapiens (human)
protein bindingSonic hedgehog proteinHomo sapiens (human)
glycosaminoglycan bindingSonic hedgehog proteinHomo sapiens (human)
peptidase activitySonic hedgehog proteinHomo sapiens (human)
zinc ion bindingSonic hedgehog proteinHomo sapiens (human)
morphogen activitySonic hedgehog proteinHomo sapiens (human)
laminin-1 bindingSonic hedgehog proteinHomo sapiens (human)
cholesterol-protein transferase activitySonic hedgehog proteinHomo sapiens (human)
cAMP-dependent protein kinase inhibitor activitySmoothened homologHomo sapiens (human)
G protein-coupled receptor activitySmoothened homologHomo sapiens (human)
patched bindingSmoothened homologHomo sapiens (human)
protein bindingSmoothened homologHomo sapiens (human)
oxysterol bindingSmoothened homologHomo sapiens (human)
protein kinase A catalytic subunit bindingSmoothened homologHomo sapiens (human)
protein sequestering activitySmoothened homologHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endocytic vesicle membraneSmoothened homologMus musculus (house mouse)
ciliary membraneSmoothened homologMus musculus (house mouse)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
Golgi membraneSonic hedgehog proteinHomo sapiens (human)
extracellular regionSonic hedgehog proteinHomo sapiens (human)
extracellular spaceSonic hedgehog proteinHomo sapiens (human)
endoplasmic reticulumSonic hedgehog proteinHomo sapiens (human)
endoplasmic reticulum lumenSonic hedgehog proteinHomo sapiens (human)
endoplasmic reticulum membraneSonic hedgehog proteinHomo sapiens (human)
Golgi apparatusSonic hedgehog proteinHomo sapiens (human)
cytosolSonic hedgehog proteinHomo sapiens (human)
plasma membraneSonic hedgehog proteinHomo sapiens (human)
cell surfaceSonic hedgehog proteinHomo sapiens (human)
membrane raftSonic hedgehog proteinHomo sapiens (human)
collagen-containing extracellular matrixSonic hedgehog proteinHomo sapiens (human)
extracellular spaceSonic hedgehog proteinHomo sapiens (human)
extracellular regionSonic hedgehog proteinMus musculus (house mouse)
nucleoplasmSonic hedgehog proteinMus musculus (house mouse)
endoplasmic reticulum lumenSonic hedgehog proteinMus musculus (house mouse)
plasma membraneSonic hedgehog proteinMus musculus (house mouse)
Golgi apparatusSmoothened homologHomo sapiens (human)
caveolaSmoothened homologHomo sapiens (human)
late endosomeSmoothened homologHomo sapiens (human)
endoplasmic reticulumSmoothened homologHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentSmoothened homologHomo sapiens (human)
centrioleSmoothened homologHomo sapiens (human)
plasma membraneSmoothened homologHomo sapiens (human)
ciliumSmoothened homologHomo sapiens (human)
endocytic vesicle membraneSmoothened homologHomo sapiens (human)
intracellular membrane-bounded organelleSmoothened homologHomo sapiens (human)
ciliary membraneSmoothened homologHomo sapiens (human)
extracellular exosomeSmoothened homologHomo sapiens (human)
ciliary tipSmoothened homologHomo sapiens (human)
9+0 non-motile ciliumSmoothened homologHomo sapiens (human)
ciliumSmoothened homologHomo sapiens (human)
dendriteSmoothened homologHomo sapiens (human)
plasma membraneSmoothened homologHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (338)

Assay IDTitleYearJournalArticle
AID1486872Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells carrying stably transfected Gli-reporter construct by luciferase reporter assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Introduction of fluorine to phenyl group of 4-(2-pyrimidinylamino)benzamides leading to a series of potent hedgehog signaling pathway inhibitors.
AID1665026Binding affinity to recombinant human Smo receptor assessed as association rate constant by SPR analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1140484Activation of VDR in mouse C3H10T1/2 cells assessed as upregulation of CYP24A1 mRNA expression at 0.5 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.
AID1650631Binding affinity to human SMO2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID596691Binding affinity to high-affinity binding site of human serum albumin at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1650623Metabolic stability in human hepatocytes assessed as intrinsic clearance measured per million cells2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID661483Inhibition of SAG-induced differentiation of mouse mesenchymal pluripotent C3H10T1/2 cells to alkaline phosphatase positive oeseoblasts at 10 uM after 6 hrs2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID1075717Inhibition of Hedgehog signaling in mouse NIH/3T3 cells assessed as down regulation of mPTCH1 mRNA expression at 10 uM2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1278070Clearance in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1383180Inhibition of porcupine in HEK293T cells transfected with pLibin-WNT3A plasmid assessed as reduction in Wnt3A secretion into cell culture medium at 100 nM after 48 hrs by Western blot method2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1650649Oral bioavailability in mouse2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1491490Inhibition of hedgehog signaling pathway in mouse NIH/3T3 Light2 cells by Gli-luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
AID1650625Protein binding in human plasma assessed as unbound fraction2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1650632Binding affinity to mouse SMO2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1067036Cmax in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID1275706Inhibition of hedgehog signalling in mouse NIH3T3 cells stably transfected with Gli-luciferase construct incubated for 48 hrs by dual luciferase reporter gene assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID1585869Activation of VDR in mouse ASZ001 cells assessed as change in Cyp24A1 mRNA expression at 5 uM after 48 hrs by q-PCR analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID447692Inhibition of hedgehog pathway in human Calu6 cells xenografted in nude mouse assessed as decrease in Gli transcription at 75 mg/kg, po bid for 3 days relative to control2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1665031Binding affinity to recombinant human Smo receptor assessed as association constant at equilibrium by SPR analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1067033Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID695424Displacement of [3H]cyclopamine from Smo D473H mutant expressed in U2OS cells at 10 uM after 2 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
AID1650624Inhibition of human ERG2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1278068Apparent volume of distribution in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1870480Inhibition of GLI in SAG induced mouse Shh Light II cells assessed as residual Smo-dependent Gli luciferase activity in starvation medium incubated for 30 hrs by dual luciferase assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1406178Inhibition of Gli1 transcriptional activity in mouse embroyonic fibroblasts up to 30 uM after 24 hrs by renilla luciferase reporter gene assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
AID1498704AUC (0 to infinity) in CD-1 mouse at 5 mg/kg, po administered as single dose by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
AID596605Binding affinity to 10 uM of human alpha-1-acid glycoprotein in at 5 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1496028Inhibition of hedgehog signaling pathway in mouse Light2 cells after 48 hrs by Gli-luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
AID1407662Antiproliferative activity against human LS180 cells after 72 hrs by sulforhodamine-B assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID596784Binding affinity to 10 uM of human alpha-1-acid glycoprotein in at 75 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1595369Antagonist activity at Smo D473H mutant receptor in mouse NIH/3T3 cells assessed as inhibition of Gli1 mRNA expression incubated for 48 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID596698Binding affinity to high-affinity binding site of rat serum albumin at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1278064Cmax in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID661558Displacement of BODIPY-labelled cyclopamine from human Smo receptor expressed in HEK293 cells after 2 hrs by fluorescence microscopy2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID1496030Anti-tumor activity against mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse assessed as tumor growth inhibition at 20 mg/kg, po administered twice daily via gavage measured every other day during compound dosing2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
AID447686Clearance in dog liver microsomes2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1407660Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium after 30 hrs by Gli-Renilla luciferase reporter gene assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1383185Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of LRP6 phosphorylation after 48 hrs by Western blot analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID760017Inhibition of Hedgehog signaling in mouse ASZ001 cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1363080Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID1727015Growth inhibition of BAEC incubated for 3 days by Coulter counter method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1665030Binding affinity to recombinant human Smo receptor assessed as maximum response at equilibrium by SPR analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1363081Half life in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID1278061Antitumor activity against human LS174T cells xenografted in BALB/C mouse assessed as tumor weight inhibition at 75 mg/kg, bid administered for 10 days measured twice per week2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1595366Antiproliferative activity against mouse Ptch+/- medulloblastoma cells assessed as inhibition of cell growth incubated for 36 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID1278060Toxicity in BALB/C mouse xenografted with human LS174T cells assessed as mortality at 75 mg/kg, bid administered for 10 days2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1407663Antiproliferative activity against human HT1080 cells after 72 hrs by sulforhodamine-B assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1763407Inhibition of hedgehog pathway in mouse Shh Light II cells transfected with Renilla luciferase and firefly luciferase incubated for 48 hrs by dual luciferase reporter gene assay2021Bioorganic & medicinal chemistry, 06-01, Volume: 39Steroidal alkaloids isolated from Veratrum grandiflorum Loes. as novel Smoothened inhibitors with anti-proliferation effects on DAOY medulloblastoma cells.
AID1075722Inhibition of smoothened (unknown origin)-mediated Shh signaling2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1278074Half life in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1068939Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID596696Binding affinity to low-affinity binding site of human serum albumin at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1665029Binding affinity to recombinant human Smo receptor assessed as dissociation rate constant by SPR analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1278066AUC (0 to t) in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID596692Binding affinity to rat alpha-1-acid glycoprotein at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1278062Inhibition of Sonic-induced hedgehog signalling in mouse NIH3T3 cells after 48 hrs by Gli-luciferase reporter assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID760014Inhibition of Hedgehog signaling in human DaOY cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1068940AUC in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID1451691Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1650641Volume of distribution at steady state in mouse2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1075715Antiproliferative activity against human DaOY cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1278077Antiproliferative activity against human PC3 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID596680Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity at 3 uM after 48 hrs by luciferase reporter gene assay in presence of 5 mg/mL human alpha-1-acid glycoprotein2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID695429Antiproliferative activity against Shh-stimulated C57BL/6 mouse granule cell precursor after 48 hrs by [3H]thymidine incorporation assay2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
AID1498701Half life in CD-1 mouse at 5 mg/kg, po administered as single dose by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
AID661485Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells at 3 uM by luciferase reporter gene assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID526560Clearance in rat at 5 mg/kg, po or 1 mg/kg, iv2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1291443Inhibition of Hh signaling pathway in mouse TM3 cells assessed as downregulation of Gli1 gene expression after 48 hrs by luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.
AID526562Thermodynamic solubility at pH 1.02010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1363078AUC in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID526559Inhibition of CYP2C92010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1650642Volume of distribution at steady state in rat2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1451683Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium at 1 uM by Gli-luciferase reporter gene assay relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID526557Inhibition of Hedgehog signaling in mouse S12 cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID695425Displacement of [3H]cyclopamine from wild type Smo expressed in U2OS cells after 2 hrs by scintillation counting2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
AID1650654Inhibition of CYP2C9 (unknown origin)2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1075724Antagonist activity at smoothened (unknown origin) expressed in mouse Shh Light2 cells co-expressing Gli-dependent reporter gene assessed as inhibition of Hh signaling by dual luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1667114Inhibition of SMO D473H mutant receptor (unknown origin) assessed as inhibition of SAG-induced Hh signaling pathway by Gli luciferase reporter cell-based assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors.
AID1650621Aqueous solubility of compound measured using solids from evaporated DMSO solution at pH 7.42020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1665032Binding affinity to recombinant human Smo receptor assessed as dissociation constant at equilibrium by SPR analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID447688Aqueous solubility at pH 12009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1664996Inhibition of hedgehog pathway in mouse NIH/3T3 cells harboring GRE-Luc assessed as inhibition of SAG-induced Hh signaling pathway by dual luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1278071Mean resident time (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1278089Antitumor activity against human LS174T cells xenografted in BALB/C mouse assessed as tumor volume inhibition at 75 mg/kg, bid administered for 10 days measured twice per week2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1278065AUC (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1068938Clearance in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID1325022Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells assessed as suppression of Gli1-mRNA expression at 0.1 uM measured after 36 hrs by RT-qPCR analysis2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID1763414Antiproliferative activity against human DAOY cells assessed as cell viability at 0.2 uM incubated for 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39Steroidal alkaloids isolated from Veratrum grandiflorum Loes. as novel Smoothened inhibitors with anti-proliferation effects on DAOY medulloblastoma cells.
AID760025Inhibition of Hedgehog signaling in mouse C3H10T1/2 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1650663Displacement of BODIPY-labeled cyclopamine from mouse SMO transfected in human HeLa cells by competition binding assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1075712Antagonist activity at smoothened in zebrafish embryo assessed as reduction in Gli-dependent RFP expression compound treated at 20 to 80 uM at 2 hrs post fertilization measured 36 hrs post fertilization2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID596780Binding affinity to 100 uM of human alpha-1-acid glycoprotein in at 5 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1727018Antiproliferative activity against mouse L1210 cells incubated for 48 hrs by Coulter counter method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1407704Effect on Renilla reniformis luciferase2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1665001Antiproliferation activity against human U251 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1665002Antiproliferation activity against human AN3CA cells assessed as reduction in cell viability incubated for 72 hr by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1379896Cytotoxicity against mouse C3H10T1/2 cells assessed as cell viability by CellTiter-Glo assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Synthesis and Investigation of
AID1664997Antiproliferation activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID596685Binding affinity to human serum albumin at 37 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1451721Inhibition of hedgehog signaling pathway in mouse Shh Light2 cells harboring Gli2 plasmid assessed as reduction in Gli2-mediated transcriptional activity at 100 nM by luciferase reporter gene assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1275704Cmax in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC-MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID760022Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Ptch mRNA expression after 24 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID596609Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 1 mg/mL human alpha-1-acid glycoprotein2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1459797Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells harboring Smo D477H mutant assessed as reduction in Gli mRNA expression by RT-PCR method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID526565Plasma concentration in Calu-6 cells xenografted nude mouse PK/PD model at 75 mg/kg, po bid for 5 days measured 4 hrs post last dose relative to untreated control2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID447685Clearance in rat liver microsomes2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1379897Inhibition of Hedgehog signaling in mouse Shh Light2 cells assessed as reduction in purmorphamine-induced Gli mediated transcriptional activity pretreated for 1 hr followed by purmorphamine addition measured after 48 hrs by luciferase reporter gene assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Synthesis and Investigation of
AID760015Activation of VDR in mouse ASZ001 cells assessed as upregulation of Cyp24A1 mRNA expression at 5 uM after 48 hrs by RT-PCR analysis relative to DMSO-treated control2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1664999Antiproliferation activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1379894Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in purmorphamine-induced increase in alkaline phosphatase level using CDP-star as substrate pretreated for 1 hr followed by purmorphamine addition measured after 5 day2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Synthesis and Investigation of
AID1383192Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3-Luc cells assessed as downregulation of Gli mRNA expression at 1 uM after 48 hrs by real-time PCR analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1650626Protein binding in mouse plasma assessed as unbound fraction2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1459794Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Smo-EGFP ciliary translocation by DAPI staining based confocal microscopic analysis2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1585882Inhibition of Hedgehog signaling pathway in Sufu-deficient mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression at 1 uM after 24 hrs by q-PCR analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1278078Antiproliferative activity against human BxPC3 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1278063Cmax in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1459787Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells measured after 24 hrs by Gli-dual luciferase reporter gene assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1451700Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells harboring sufu shRNA assessed as downregulation of ptch1 mRNA expression at 100 nM by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1665059Acute toxicity in Kunming mouse assessed as lethality through intragastric administration observed for 14 days2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1067037Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells after 48 hrs by Gli-luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID596778Binding affinity to high-affinity site of human alpha-1-acid glycoprotein at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1493634Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
AID1068943Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells by Gli1-luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID1057692Inhibition of SHH signaling pathway in mouse NIH3T3 cells measured after 48 hrs by Gli-luciferase reporter assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID1650622Metabolic stability in rat hepatocytes assessed as intrinsic clearance measured per million cells2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1278067Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1451698Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells harboring sufu shRNA assessed as downregulation of Gli1 mRNA expression at 100 nM by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1451687Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID596782Binding affinity to 20 uM of human alpha-1-acid glycoprotein in at 25 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1275705AUC (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC-MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID661553Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells by luciferase reporter gene assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID1275708Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC-MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID1493632Cytotoxicity against human T47D cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
AID596608Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 0.5 mg/mL human alpha-1-acid glycoprotein2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1650645Half life in mouse2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1140482Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells assessed as residual activity at 0.5 uM after 24 hrs by RT-PCR analysis relative to 20alpha-hydroxycholesterol/22(S)-hydroxycholesterol2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.
AID1665000Antiproliferation activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID596785Binding affinity to 20 uM of human alpha-1-acid glycoprotein in at 75 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID661484Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells at 0.3 uM by luciferase reporter gene assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID661552Inhibition of SAG-induced differentiation of mouse mesenchymal pluripotent C3H10T1/2 cells to alkaline phosphatase positive oeseoblasts after 6 hrs2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID1458764Displacement of [3H]-cyclopamine from human wild-type SMO receptor expressed in HEK293T cell membranes by liquid scintillation spectrometry2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
AID1650627Drug level in mouse plasma at 40 mg/kg, po administered as single dose measured after 1 hr2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1650620Lipophilicity, logD of compound2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1075714Antiproliferative activity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1451720Inhibition of hedgehog signaling pathway in mouse Shh Light2 cells harboring Gli1 plasmid assessed as reduction in Gli1-mediated transcriptional activity at 100 nM by luciferase reporter gene assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1303793Inhibition of hedgehog signaling (unknown origin) expressed in mouse NIH/3T3 cells by Gli-dual-luciferase reporter assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Synthesis and evaluation of novel benzylphthalazine derivatives as hedgehog signaling pathway inhibitors.
AID1665047Inhibition of hedgehog pathway in human MDA-MB-468 cells assessed as decrease in Smo protein levels in cilia at 28 uM incubated for 24 hrs by immunostaining based confocal microscopic analysis2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1075716Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1383183Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of Axin2 mRNA expression after 24 hrs by real-time PCR analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1498703AUC (0 to t) in CD-1 mouse at 5 mg/kg, po administered as single dose by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
AID1383186Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3 cells expressing GRE-Luc reporter gene assessed as inhibition of SAG-induced GRE-Luc reporter activity after 48 hrs by luminescence assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID526556Inhibition of Hedgehog signaling in human HEPM cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1870484Inhibition of GLI in SAG induced mouse Sufu-KO-LIGHT cells assessed as residual Smo-independent Gli luciferase activity in starvation medium incubated for 30 hrs by dual luciferase assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1068937Mean residence time (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID596702Binding affinity to human alpha-1-acid glycoprotein at 20 degC by isothermal titration calorimetry analysis2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1664998Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs measured after 4 hrs by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1140496Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of (1R,3aR,4S,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-1H-inden-4-yl 3-hydroxybenzoate2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.
AID1278069Clearance in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1650646Half life in rat2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1665055Acute toxicity in Kunming mouse assessed as mortality at 1111 mg/kg, ig observed for 14 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1451689Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1275711Half life in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC/MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID1179712Inhibition of hedgehog receptor signaling pathway in mouse NIH3T3 cells transfected with Gli-reporter gene by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Five-membered heteroaromatic ring fused-pyrimidine derivatives: design, synthesis, and hedgehog signaling pathway inhibition study.
AID1278073Half life in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1650638Clearance in rat2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1239805Inhibition of SMO in mouse NIH/3T3 cells assessed as inhibition of SAG-induced hedgehog-mediated luminescence signaling by GRE-luciferase reporter gene assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
AID596703Binding affinity to rat alpha-1-acid glycoprotein at 20 degC by isothermal titration calorimetry analysis2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID668854Inhibition of Smo in mouse C3H10T1/2 cells using human recombinant SHH assessed as effect on SMO/SHH transient transcriptional activation after 20 hrs by Gli-luciferase reporter assay2012ACS medicinal chemistry letters, Feb-09, Volume: 3, Issue:2
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
AID596689Binding affinity to low-affinity site of human alpha-1-acid glycoprotein at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID447684Inhibition of SHH in mouse C3H10T1/2 cells by Gli-luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1665003Antiproliferation activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1650656Inhibition of CYP1A2 (unknown origin)2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1067034Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID596699Binding affinity to low-affinity binding site of rat serum albumin at 20 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1595368Antagonist activity at Smo receptor in mouse NIH/3T3 cells assessed as inhibition of Gli1 mRNA expression incubated for 48 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID1291444Cytotoxicity against mouse TM3 cells assessed as cell viability after 48 hrs by Cell Titer Glo assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.
AID1493635Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
AID1650662Displacement of BODIPY-labeled cyclopamine from human SMO transfected in human HeLa cells by competition binding assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID447689Aqueous solubility at pH 6.52009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1379899Cytotoxicity against mouse Shh Light2 cells assessed as cell viability by CellTiter Glo assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Synthesis and Investigation of
AID760011Activation of VDR in human DaOY cells assessed as upregulation of Cyp24A1 mRNA expression at 2.5 uM after 48 hrs by RT-PCR analysis relative to DMSO-treated control2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1650665Inhibition of SMO-mediated hedgehog signalling pathway in human HPEM cells by luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1140463Solubility of the compound2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Scaffold hopping approach to a new series of smoothened antagonists.
AID1650629Inhibition of GLI mRNA expression in mouse xenografted with human COLO205 cells at 40 mg/kg, po administered as single dose measured after 8 hrs by RT-PCR analysis relative to control2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1595365Displacement of BODIPY-Cyclopamine from human HA-tagged Smo receptor expressed in human U2OS cells at 1 to 10000 nM incubated for 2 hrs by DAPI staining based fluorescence microscopic method2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID1383184Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of disheveled 2 phosphorylation after 48 hrs by Western blot analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID760024Inhibition of Hedgehog signaling in mouse C3H10T1/2 cells assessed as downregulation of Ptch mRNA expression after 24 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1595364Antagonist activity at Smo receptor in mouse NIH/3T3 cells harboring GRE-Luc assessed as inhibition of SAG-induced Hh signaling pathway preincubated with cells followed by SAG addition measured after 48 hrs by luciferase reporter gene assay2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID1325027Antagonist activity at wild-type Smo (unknown origin) expressed in mouse Shh Light2 cells assessed as suppression of Gli-mRNA expression measured after 36 hrs by dual luciferase reporter gene assay2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID1068936Half life in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID1140464Inhibition of Smo receptor (unknown origin) expressed in NIH3T3 cells assessed as inhibition of Smo agonist SAG-induced GRE activation after 30 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
Scaffold hopping approach to a new series of smoothened antagonists.
AID1650655Inhibition of CYP2C19 (unknown origin)2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1727016Antiproliferative activity against human HeLa cells incubated for 4 days by Coulter counter method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID596781Binding affinity to 10 uM of human alpha-1-acid glycoprotein in at 25 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID447694Antitumor activity against mouse medulloblastoma cells xenografted in Ptch +/- mouse assessed as decrease in tumor volume at 12.5 mg/kg, po bid2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1278072Mean resident time (0 to t) in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1075718Inhibition of hedgehog signaling in mouse MSC cells assessed as down regulation of alkaline phosphatase at 20 to 80 uM2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1650633Protein binding in rat plasma assessed as unbound fraction2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID596682Binding affinity to rat alpha-1-acid glycoprotein at 250 uM at 37 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID447695Fraction unbound in human Calu6 cells xenografted in nude mouse plasma at 75 mg/kg, po bid measured after 4 hrs post fifth dose2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1771775Antagonist activity at SMO in mouse NIH3T3 cells preincubated for 2 hrs followed by SAG stimulation and measured after 24 hrs by Bright-Glo luciferase assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
AID1491491Antiproliferative activity against Ptch+/- and p53-/- mouse medulloblastoma cells after 36 hrs by Brdu incorporation assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
AID1278076Antiproliferative activity against human LS174T cells after 72 hrs by CellTiter-Glo luminescent cell viability assay2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID447691Inhibition of SHH in human HEPM cells by Gli-luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID1379901Inhibition of recombinant human C-terminal His6-tagged alkaline phosphate activity (Leu18 to Ser502 residues) using CDP-star as substrate pretreated for 30 mins followed by substrate addition measured after 60 mins by luminescence assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Synthesis and Investigation of
AID526570Antitumor activity in mouse medulloblastoma allograft model harboring tumors with activating mutations in Hh pathway (Ptch+/-) assessed as inhibition of tumor growth at 5 mg/kg, po bid2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1275709Clearance in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC-MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID1075713Antiproliferative activity against human SW1353 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
AID1585862Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression at 5 uM after 24 hrs by q-PCR analysis relative to oxysterol alone2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1727014Growth inhibition of HMEC-1 incubated for 4 days by Coulter counter method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1363076Inhibition of Hedgehog signaling pathway in mouse NIH/3T3 cells assessed as reduction in Sonic hedgehog-induced Gli luciferase activity after 48 hrs by Dual-luciferase reporter gene assay2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID526558Inhibition of CYP3A42010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID596681Binding affinity to human alpha-1-acid glycoprotein at 37 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID692749Allosteric inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of purmorphamine-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCr analysis2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.
AID1870485Inhibition of GLI in SAG induced mouse Sufu-KO-LIGHT cells assessed as residual Smo-independent Gli luciferase activity in starvation medium at 100 nM incubated for 30 hrs by dual luciferase assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1665058Acute toxicity in Kunming mouse assessed as mortality at 4000 mg/kg, ig observed for 14 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1870483Inhibition of GLI in mouse ASZ001 cells assessed as reduction in cell viability in starvation medium incubated for 48 hrs by CellTiter assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1275710Mean residence time (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv measured during 2 mins to 24 hrs period post dose by LC/MS/MS method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Synthesis and pharmacological evaluation of trifluoromethyl containing 4-(2-pyrimidinylamino)benzamides as Hedgehog signaling pathway inhibitors.
AID1664993Antiproliferation activity against human T47D cells assessed as reduction in cell viability incubated for 72 hr by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1496027Inhibition of hedgehog signaling pathway in mouse Light2 cells at 100 nM after 48 hrs by Gli-luciferase reporter gene assay relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
AID596783Binding affinity to 100 uM of human alpha-1-acid glycoprotein in at 25 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1067035AUC in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID1493633Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
AID1585865Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression after 24 hrs by q-PCR analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1068941Cmax in Sprague-Dawley rat at 1 mg/kg, iv2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.
AID1383152Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells assessed as suppression of Wnt signaling after 48 hrs by Super-top flash reporter gene assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID661482Antiproliferative activity against SAG-induced rat cerebellar granule cell precursors by [3H]-thymidine incorporation assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
AID1498700Tmax in CD-1 mouse at 5 mg/kg, po administered as single dose by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
AID1897746Inhibition of AhR mRNA expression in purmorphamine treated mouse C3H 10T1/2 cells at 1 uM incubated for 48 to 96 hrs by RT-qPCR analysis2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
The Highly Potent AhR Agonist Picoberin Modulates Hh-Dependent Osteoblast Differentiation.
AID1665054Acute toxicity in Kunming mouse assessed as mortality at 741 mg/kg, ig observed for 14 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1650637Clearance in mouse2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1140493Inhibition of hedgehog signaling pathway-mediated PTCH mRNA expression in mouse ASZ001 cells up to 10 uM after 24 hrs by RT-PCR analysis2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.
AID1498702Cmax in CD-1 mouse at 5 mg/kg, po administered as single dose by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Design, synthesis and biological evaluation of deuterated Vismodegib for improving pharmacokinetic properties.
AID1278075Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2016European journal of medicinal chemistry, Mar-03, Volume: 110Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
AID1665056Acute toxicity in Kunming mouse assessed as mortality at 1778 mg/kg, ig observed for 14 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1451724Antiproliferative activity against mouse Ptch+/- p53-/- medulloblastoma cells assessed as reduction in cell proliferation up to 30 uM after 72 hrs by MTS assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1665062Toxicity in BALB/c mouse xenografted with human MDA-MB-468 cells assessed as body weight at 80 to 100 mg/kg, ig measured every day for 21 day2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID596607Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID760023Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by RT-PCR analysis2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1451682Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium by Gli-luciferase reporter gene assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID1650619Inhibition of SMO-mediated Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in sonic hedgehog-induced osteoblast differentiation by measuring alkaline phosphatase activity incubated for 72 hrs2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1585866Activation of VDR in mouse C3H10T1/2 cells assessed as change in Cyp24A1 mRNA expression at 5 uM after 24 hrs by q-PCR analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID447687Plasma concentration in human Calu6 cells xenografted in nude mouse at 75 mg/kg, po bid measured after 4 hrs post fifth dose2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
GDC-0449-a potent inhibitor of the hedgehog pathway.
AID692745Competitive inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of SAG-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCR analysis2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.
AID1727017Antiproliferative activity against human CEM cells incubated for 96 hrs by Coulter counter method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1665057Acute toxicity in Kunming mouse assessed as mortality at 2667 mg/kg, ig observed for 14 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID1407661Inhibition of hedgehog signaling pathway-mediated differentiation of mouse C3H10T1/2 cells assessed as decrease in SAG-induced ALP activity after 6 days by chemiluminescence-based assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID596687Binding affinity to rat serum albumin at 37 degC by surface plasmon resonance assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1458765Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
AID1067032Mean residence time (0 to t) in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID760019Activation of VDR in mouse M210B4 cells assessed as upregulation of Cyp24A1 mRNA expression at 1 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.
AID1459796Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells expressing wild type Smo assessed as reduction in Gli mRNA expression by RT-PCR method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1325037Antiproliferative activity against mouse medulloblastoma cells isolated from Ptch+/- p53-/- mouse measured after 72 hrs by MTS assay2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID1140497Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of VD32014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.
AID695428Antagonist activity at Smo in mouse Shh-Light 2 cells assessed as inhibition of Shh-induced Gli1-reporter activity after 2 days by dual-luciferase reporter gene method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
AID1325018Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells by Gli-luciferase reporter gene assay2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
AID1363079Apparent volume of distribution in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID1650650Oral bioavailability in rat2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1665004Cytotoxicity against human MCF10A cells assessed as cell viability incubated for 72 hrs measured by MTT assay2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID596606Binding affinity human alpha-1-acid glycoprotein in after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1363077Cmax in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.
AID526564Inhibition of Hedgehog signaling in Calu-6 cells xenografted nude mouse PK/PD model assessed as reduction in Gli1 mRNA expression at 75 mg/kg, po bid for 5 days measured 4 hrs post last dose relative to untreated control2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1870482Inhibition of GLI in SAG induced mouse C3H10T1/2 cells assessed reduction Gli-dependent differentiation by measuring ALP activity incubated for 48 hrs by chemiluminescence assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1873212Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells assessed as BODIPY-Prazosin uptake and measured after 2 hrs by FACScan flow cytometry analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1459795Inhibition of hedgehog signaling pathway expressed in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Gli-2 accumulation at tip of primary cilia by DAPI staining based confocal microscopic analysis2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1595367Cytotoxicity activity human U251 cells assessed as reduction of cell viability upto 1000 nM incubated for 48 hrs by CCK-8 assay2019European journal of medicinal chemistry, Jun-15, Volume: 172Structural optimization on a virtual screening hit of smoothened receptor.
AID1870481Inhibition of GLI in SAG induced mouse Shh Light II cells assessed as residual Smo-dependent Gli luciferase activity in starvation medium at 100 nM incubated for 30 hrs by dual luciferase assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Indolactam Dipeptides as Nanomolar Gli Inhibitors.
AID1451693Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID596704Binding affinity to human serum albumin at 20 degC by isothermal titration calorimetry analysis2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1650652Inhibition of CYP3A4 (unknown origin)2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1650653Inhibition of CYP2D6 (unknown origin)2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1360315Antagonist activity at Smo receptor in mouse NIH/3T3 cells harboring GRE-Luc assessed as inhibition of SAG-induced Hh signaling pathway preincubated with cells followed by SAG addition measured after 48 hrs by luciferase reporter gene assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
AID509548Antagonist activity at hedgehog receptor2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Modulators of the hedgehog signaling pathway.
AID1585868Inhibition of Hedgehog signaling pathway in mouse ASZ001 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression after 48 hrs by q-PCR analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1650628Drug level in mouse plasma at 40 mg/kg, po administered as single dose measured after 8 hrs2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AID1585881Inhibition of Hedgehog signaling pathway in Sufu-deficient mouse C3H10T1/2 cells assessed as reduction in oxysterol-induced Gli1 mRNA expression at 5 uM after 24 hrs by q-PCR analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Synthesis and evaluation of third generation vitamin D3 analogues as inhibitors of Hedgehog signaling.
AID1067031Elimination half life in Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
AID596779Binding affinity to 20 uM of human alpha-1-acid glycoprotein in at 5 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID1459798Selectivity ratio of IC50 for hedgehog signaling pathway in mouse NIH/3T3 cells harboring Smo D477H mutant to IC50 for hedgehog signaling pathway in mouse NIH/3T3 cells expressing wild type Smo2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1451725Induction of apoptosis in mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse at 12.5 mg/kg, ip bid for 15 consecutive days by TUNEL assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
AID596786Binding affinity to 100 uM of human alpha-1-acid glycoprotein in at 75 uM after 6 hrs by equilibrium dialysis method2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
AID351760Inhibition of SHH in mouse Shh Light2 cells by GLI-responsive firefly luciferase reporter gene assay2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Hedgehog-Gli signaling pathway inhibitors as anticancer agents.
AID1665060Antitumour activity against human MDA-MB-468 cells xenografted in BALB/c mouse assessed as reduction in tumour volume at 100 mg/kg, ig measured every 2 days for 21 days relative to control2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
AID526563Thermodynamic solubility at pH 6.52010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345944Human SMO (Class Frizzled GPCRs)2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (636)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (1.89)29.6817
2010's463 (72.80)24.3611
2020's161 (25.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.60 (24.57)
Research Supply Index6.60 (2.92)
Research Growth Index6.35 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials68 (10.21%)5.53%
Reviews114 (17.12%)6.00%
Case Studies120 (18.02%)4.05%
Observational4 (0.60%)0.25%
Other360 (54.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]